The two-year awards were made by NCI's operations and technical support contractor, Science Applications International Corp.-Frederick. Samir Hanash, of the University of
The researchers will use transgenic mouse models of human cancers to study current proteomic technologies, compare results, and provide reference data sets and biological resources for widespread research use, NCI said. According to the institute, once complete, the project will yield the first reliable and broad-based technological platform for the discovery and clinical validation of protein biomarkers for cancer.
Data and information from the project will be integrated and distributed through the Biomedical Informatics Grid.